Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24].
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, Lemiale V. Meert AP, et al. Among authors: rousseau bussac g. Bull Cancer. 2023 Apr;110(4):467-468. doi: 10.1016/j.bulcan.2023.02.001. Epub 2023 Feb 17. Bull Cancer. 2023. PMID: 36805208 No abstract available.
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study.
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, Lemiale V. Meert AP, et al. Among authors: rousseau bussac g. Bull Cancer. 2022 Sep;109(9):916-924. doi: 10.1016/j.bulcan.2022.04.014. Epub 2022 Jun 16. Bull Cancer. 2022. PMID: 35718570
ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V. Toffart AC, et al. Among authors: rousseau bussac g. Ann Intensive Care. 2023 Apr 18;13(1):29. doi: 10.1186/s13613-023-01122-z. Ann Intensive Care. 2023. PMID: 37072645 Free PMC article.
[Supportive cares on thoracic oncology].
Rousseau-Bussac G, Crequit P, Masanes MJ, Chouaïd C. Rousseau-Bussac G, et al. Bull Cancer. 2012 Nov;99(11):1057-64. doi: 10.1684/bdc.2012.1650. Bull Cancer. 2012. PMID: 23073345 Free article. Review. French.
[Targeted agents in the treatment of lung cancer].
Staudacher L, Teixeira L, Kempf E, Rousseau-Bussac G, Jouveshomme S, Cohen R, Beuzelin C, Jagot JL, Salmeron S, Trédaniel J. Staudacher L, et al. Pathol Biol (Paris). 2012 Aug;60(4):246-53. doi: 10.1016/j.patbio.2012.05.011. Epub 2012 Jun 26. Pathol Biol (Paris). 2012. PMID: 22743094 Review. French.
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
Akli A, Girard N, Fallet V, Rousseau-Bussac G, Gounant V, Friard S, Trédaniel J, Dujon C, Wislez M, Duchemann B, Giroux-Leprieur E. Akli A, et al. Among authors: rousseau bussac g. Target Oncol. 2022 Nov;17(6):675-682. doi: 10.1007/s11523-022-00915-9. Epub 2022 Sep 21. Target Oncol. 2022. PMID: 36129569
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C. Descourt R, et al. Among authors: rousseau bussac g. Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14. Lung Cancer. 2019. PMID: 31491676 Free article.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Mehlman C, et al. Among authors: rousseau bussac g. Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28. Lung Cancer. 2019. PMID: 31600593
18 results